The single most important correction to the model stack is the thesis evaluation's "38x P/E" headline, which is simply wrong on a trailing-twelve-month basis. TTM net income through June 2026 is $117.6M + $255.5M + $268.2M + $171.5M = $812.8M, which against a $17.65B market cap gives 21.7x, not 38x. The 38x figure only works if you divide by the 2024 calendar-year earnings of $464.8M, which is a stale, pre-recovery number. That error cascades: the thesis score of -16, the "38x earnings on a 6% margin" framing, and the reverse-DCF implying 26.6% FCF growth all inherit a bearish bias that the actual TTM data doesn't support. The TTM net margin is 8.7%, not 6%, and the quarterly trajectory — from a $84.7M loss in September 2024 to $268.2M in March 2026 — shows a genuine, multi-quarter earnings recovery, not a one-off. I'm not saying the recovery is permanent; I'm saying the models are arguing against a ghost.

Where I do agree with the bearish lean is on the structural revenue problem. Five years of annual revenue sit in a narrow $7.85B–$8.77B band, and the TTM figure of roughly $9.32B (summing the four most recent quarters) is only modestly above the 2021 peak. This is not a growth story. The FCF CAGR of -52.5% over the measured window is the scariest number in the file, and the 85.4% payout ratio means Franklin Templeton is returning nearly all cash as dividends, leaving little reinvestment capacity. The "alternatives re-rating" narrative the market is pricing in is real but still a minority of the $1.3T+ AUM base, and the data file contains zero segment-level AUM, fee-rate, or client-flow breakdowns to verify whether that alternatives book is actually compounding or just riding a one-year private-credit rally. The 1.68M-share insider sale on July 20, 2026 — roughly $58M at the current price — is a concrete yellow flag that the "Net Insider Buying" secondary signal completely buries; the F-InKind entries on August 31 are in-kind transfers, not open-market purchases, and should not be counted as buying.

The valuation synthesis's $18.63 fair value is, in my view, too low by a wide margin. A DCF that produces $18.63 on a company generating $912M in FCF, holding $1.21B in net cash, and paying a 3.77% dividend is implicitly assuming near-zero growth and a very low terminal multiple — perhaps 8-9x FCF — which is below what the market pays for any investment-grade financial. Even granting that fee compression is structural and that the alternatives premium is overblown, a 12-14x FCF multiple on $912M growing at 3-4% for five years, plus net cash, lands closer to $28-32 per share. That still puts the stock 8-20% above fair value at $34.73, not 46%. The 1.25x P/B and 1.93x P/S are unremarkable for a financial; the 16.1x EV/EBITDA is where the premium lives, and it's defensible only if the EBITDA base holds. The 52% gap between annual and TTM ROE flagged in the anomaly list is the key tell: the business is mid-recovery, and the TTM number flatters the trend while the annual number flatters the trough.

The contrarian case for owning at $34.73 is narrower than the models give credit for: a 3.77% dividend yield with a net-cash balance sheet and 22x earnings is not a bubble, it's a rich-but-defensible income position if you believe the TTM earnings level is the floor, not the peak. The risk is that the TTM recovery is driven by a 2025-26 equity-market rally inflating AUM and performance fees, and that a 10% drawdown in public markets knocks $100-150M off quarterly earnings, pushing the P/E back toward 30x+ on a shrinking earnings base. Without segment data, I can't size that risk precisely, and that data thinness is itself a reason to stay at the margin. The models are directionally right that the stock is overvalued, but the magnitude is overstated by the stale-earnings error, and the "alternatives platform" narrative, while overpriced, is not pure fiction.